CHI's 9th Annual Liquid Biopsy for Disease Management

CHI's 9th Annual Liquid Biopsy for Disease Management conference will review new liquid biopsies coming on the market that have the sensitivity and robustness required for clinical applications, including measuring treatment response, diagnosing disease recurrence, detecting multicancer at early stages, assessing minimal residue disease, monitoring disease progression, and determining prognosis. A thorough investigation of biomarkers and their clinical translation will be evaluated, including cfDNA, exosomes, EVs, CTCs, and supermeres. This conference is a part of the Next Generation Dx Summit.